Xenon Pharmaceuticals (XENE) Stock: Buy, Sell, or Hold?
XENE - Xenon Pharmaceuticals Inc
$39.75
-17.60 (-30.69%)
▼
5d:
-32.23%
30d:
-36.22%
90d:
-24.87%
WAIT
LOW Confidence
Analysis Updated: Sep 18, 2026 12:00 AM ET
Earnings: Nov 02, 2026
Get Alerted When XENE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: XENE is down 32.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: XENE is down 32.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: XENE is currently trading at $39.75, which is considered oversold relative to its 30-day fair value range of $55.54 to $64.40.
Technical Outlook: Technically, XENE is in a uptrend. The price is currently testing key support at $39.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 30.7% recently.
Market Sentiment: XENE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $81.21 (+104.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XENE is in a uptrend. The price is currently testing key support at $39.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 30.7% recently.
Market Sentiment: XENE scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $81.21 (+104.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$55.54 -
$64.40
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding XENE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-30.7%)
- BULLISH: Trading 104.3% below Wall St target ($81.21)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$55.54 -
$64.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$39.08
Resistance Level
$60.57
Current Trend
Uptrend
Technical data as of
Sep 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.28
Wall Street Target
$81.21
(+104.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 20, 2026 10:53 AM ET
Data refreshes hourly during market hours. Next update: 11:53 AM
Data refreshes hourly during market hours. Next update: 11:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XENE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 49 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$849 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$291 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 54 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$34 | 63 BUY |
Advanced XENE Option Strategies
Professional options setups generated by AI based on today's XENE price and gamma walls.